Stock Scorer

ADC Therapeutics SA (ADCT)

ADC Therapeutics SA reported revenue of 19.2M USD for the quarter ending 30 June 2026, up 2.2% from 18.8M a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '26 · ending 30 June 2026 19.2M +2.2%
Operating Income Q2 '26 · ending 30 June 2026 -25.4M —
Net Income Q2 '26 · ending 30 June 2026 -16.6M —
Cost of Revenue Q4 '23 · ending 31 December 2023 254K -48.1%
Operating Cash Flow Q2 '26 · ending 30 June 2026 -11.8M —
Free Cash Flow Q2 '26 · ending 30 June 2026 -11.8M —
Shares Outstanding Q2 '26 · ending 30 June 2026 155M +44.6%
EPS Q2 '26 · ending 30 June 2026 -0.60 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 81.4M-121.5M-142.6M-141.4M
20242024-12-31 70.8M-130.7M-157.8M-124.7M
20232023-12-31 69.6M-166M-240.1M-121.9M
20222022-12-31 209.9M-123.3M-157.1M-139M
20212021-12-31 33.9M-261.7M-230M-236.8M
20202020-12-31 0-219.3M-246.3M-169.5M
20192019-12-31 2.3M-119.4M-116.5M-121.9M
20182018-12-31 1.1M-125.9M-123.1M-122.3M

Every period

Revenue Quarterly

PeriodEndingRevenue
Q2 '262026-06-3019.2M
Q1 '262026-03-3120.9M
Q4 '252025-12-3123.1M
Q3 '252025-09-3016.4M
Q2 '252025-06-3018.8M
Q1 '252025-03-3123M
Q4 '242024-12-3116.9M
Q3 '242024-09-3018.5M
Q2 '242024-06-3017.4M
Q1 '242024-03-3118.1M
Q4 '232023-12-3116.8M
Q3 '232023-09-3014.5M
Q2 '232023-06-3019.3M
Q1 '232023-03-3119M
Q4 '222022-12-3169.8M
Q3 '222022-09-3076.3M
Q2 '222022-06-3017.3M
Q1 '222022-03-3146.5M
Q4 '212021-12-3117M
Q3 '212021-09-3013.1M

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-30-25.4M
Q1 '262026-03-31-25.2M
Q4 '252025-12-31-17.9M
Q3 '252025-09-30-31M
Q2 '252025-06-30-44.1M
Q1 '252025-03-31-28.5M
Q4 '242024-12-31-32.4M
Q3 '242024-09-30-35.6M
Q2 '242024-06-30-29M
Q1 '242024-03-31-33.6M
Q4 '232023-12-31-40M
Q3 '232023-09-30-36.1M
Q2 '232023-06-30-39.6M
Q1 '232023-03-31-50.2M
Q4 '222022-12-31-10.7M
Q3 '222022-09-30-3.1M
Q2 '222022-06-30-69.4M
Q1 '222022-03-31-40.4M
Q4 '212021-12-31-62.8M
Q3 '212021-09-30-57.8M

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-30-16.6M
Q1 '262026-03-31-33M
Q4 '252025-12-31-6.4M
Q3 '252025-09-30-41M
Q2 '252025-06-30-56.6M
Q1 '252025-03-31-38.6M
Q4 '242024-12-31-30.7M
Q3 '242024-09-30-44M
Q2 '242024-06-30-36.5M
Q1 '242024-03-31-46.6M
Q4 '232023-12-31-85M
Q3 '232023-09-30-46.7M
Q2 '232023-06-30-48.9M
Q1 '232023-03-31-59.4M
Q4 '222022-12-31-24.2M
Q3 '222022-09-30-50.6M
Q2 '222022-06-30-64.4M
Q1 '222022-03-31-16.7M
Q4 '212021-12-31-34.4M
Q3 '212021-09-30-71.5M

Cost of Revenue Quarterly

PeriodEndingCost of Revenue
Q4 '232023-12-31254K
Q3 '232023-09-30366K
Q2 '232023-06-301.3M
Q1 '232023-03-31590K
Q4 '222022-12-31489K
Q3 '222022-09-301.3M
Q2 '222022-06-302.3M
Q1 '222022-03-31529K
Q4 '212021-12-31770K
Q3 '212021-09-30502K
Q2 '212021-06-30121K
Q1 '212021-03-310
Q4 '202020-12-310
Q3 '202020-09-300
Q2 '202020-06-300
Q1 '202020-03-310

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-30-11.8M
Q1 '262026-03-31-29.7M
Q4 '252025-12-31-31.1M
Q3 '252025-09-30-29.6M
Q2 '252025-06-30-24.1M
Q1 '252025-03-31-56.3M
Q4 '242024-12-31-21.9M
Q3 '242024-09-30-25M
Q2 '242024-06-30-32.8M
Q1 '242024-03-31-44.1M
Q4 '232023-12-31-31.6M
Q3 '232023-09-30-36.7M
Q2 '232023-06-30-35M
Q1 '232023-03-31-15.4M
Q4 '222022-12-31-52.1M
Q3 '222022-09-302.2M
Q2 '222022-06-30-53M
Q1 '222022-03-31-33.9M
Q4 '212021-12-31-61.6M
Q3 '212021-09-30-58.6M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q2 '262026-06-30-11.8M
Q1 '262026-03-31-29.7M
Q4 '252025-12-31-31.1M
Q3 '252025-09-30-29.6M
Q2 '252025-06-30-24.1M
Q1 '252025-03-31-56.6M
Q4 '242024-12-31-21.9M
Q3 '242024-09-30-25.3M
Q2 '242024-06-30-32.9M
Q1 '242024-03-31-44.6M
Q4 '232023-12-31-32M
Q3 '232023-09-30-37.3M
Q2 '232023-06-30-36.2M
Q1 '232023-03-31-16.4M
Q4 '222022-12-31-52.2M
Q3 '222022-09-302M
Q2 '222022-06-30-53.1M
Q1 '222022-03-31-34.1M
Q4 '212021-12-31-62.1M
Q3 '212021-09-30-60M

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-30155M
Q1 '262026-03-31154.1M
Q3 '252025-09-30136.4M
Q2 '252025-06-30113.7M
Q1 '252025-03-31107.2M
Q3 '242024-09-30104.8M
Q2 '242024-06-3095.7M
Q1 '242024-03-3182.6M
Q3 '232023-09-3082.3M
Q2 '232023-06-3081.5M
Q1 '232023-03-3180.8M
Q3 '222022-09-3078.4M
Q2 '222022-06-3076.9M
Q1 '222022-03-3176.8M
Q3 '212021-09-3076.7M
Q2 '212021-06-3076.7M
Q1 '212021-03-3176.7M
Q3 '202020-09-3070.9M
Q2 '202020-06-3062.9M
Q1 '202020-03-3151M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q2 '262026-06-30-0.60
Q1 '262026-03-31-0.99
Q4 '252025-12-31-1.14
Q3 '252025-09-30-1.43
Q2 '252025-06-30-1.55
Q1 '252025-03-31-1.43
Q4 '242024-12-31-1.63
Q3 '242024-09-30-2.40
Q2 '242024-06-30-2.55
Q1 '242024-03-31-2.77
Q4 '232023-12-31-2.94
Q3 '232023-09-30-2.20
Q2 '232023-06-30-2.28
Q1 '232023-03-31-2.52
Q4 '222022-12-31-2.01